The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme:: a prospective, randomised study

被引:64
作者
De Francesco, V
Zullo, A
Hassan, C
Della Valle, N
Pietrini, L
Minenna, MF
Winn, S
Monno, R
Stoppino, V
Morini, S
Panella, C
Ierardi, E
机构
[1] Univ Foggia, Dept Med Sci, Gastroenterol Sect, Riuniti Hosp, I-71100 Foggia, Italy
[2] Nuovo Regina Margher Hosp, Gastroenterol & Digest Endoscopy Unit, Rome, Italy
[3] Univ Foggia, Gastroenterol Unit, Riuniti Hosp, I-71100 Foggia, Italy
[4] Univ Bari, Dept Med & Publ Hlth, Hyg Sect, Bari, Italy
关键词
Helicobacter pylori; sequential therapy; treatment duration; triple therapy;
D O I
10.1016/j.dld.2003.12.015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aim. One-week triple therapy for Helicobacter pylori revealed, during these last few years, a decrease in the eradication rate, so that the prolongation of its duration has been proposed. A sequential scheme recently showed very satisfactory results. We performed a prospective randomised study with the aim of either evaluating whether the triple therapy prolongation may improve its effectiveness and comparing its outcome with that of sequential regimen. Patients and methods. Three hundred and forty-two H. pylori positive patients completed the study. They were randomised to receive one of the following treatments: (i) a 7-day triple therapy comprising of rabeprazole (20mg, b.i.d.) plus clarithromycin (500mg, b.i.d.) and amoxycillin (1 g, b.i.d.); (ii) a 10-day triple therapy comprising the same scheme; (iii) a 10-day sequential regimen comprising of rabeprazole (20 mg, b.i.d.) plus amoxycillin (1 g, b.i.d.) for 5 days followed by rabeprazole (20 mg b.i.d.) plus clarithromycin (500 mg, b.i.d.) and tinidazole (500 mg, b.i.d.) for the next 5 days. Therapeutic results were expressed using both intention-to-treat and per protocol analyses with 95% confidence intervals. A model of multivariate logistic regression analysis was performed using therapeutic outcome as a dependent variable and including endoscopic finding, smoking habit, age and sex as candidates for the model. Results. Sequential regimen showed a significant gain in the eradication rate as compared to the 7-day (P < 0.0001) and the 10-day (P < 0.01) triple therapies, respectively. Overall eradication was lower in smokers than in non-smokers, but the difference remained significant only in the 7-day triple therapy (P < 0.01). Additionally, the overall eradication was higher in peptic ulcer than dyspepsia (P < 0.01), even if this difference was significant only for both triple therapies. Conclusions. Seven-day triple therapy achieves disappointing eradication rates in dyspeptics and smokers. prolonging triple therapy to 10 days does not significantly improve the eradication rate. The novel 10-day sequential regimen is more effective and equally tolerated than the 10-day triple therapy. (C) 2004 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:322 / 326
页数:5
相关论文
共 34 条
[1]   CIGARETTE-SMOKING AND HELICOBACTER-PYLORI INFECTION [J].
BATESON, MC .
POSTGRADUATE MEDICAL JOURNAL, 1993, 69 (807) :41-44
[2]   Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type:: management of the disease [J].
Bayerdöffer, E ;
Morgner, A .
DIGESTIVE AND LIVER DISEASE, 2000, 32 (03) :192-194
[3]  
Bazzoli F, 2000, GUT, V47, pA79
[4]  
Bazzoli F, 2000, DIGEST LIVER DIS, V32, pS207
[5]  
Bigard MA, 1998, ALIMENT PHARM THER, V12, P383
[6]   One-week triple vs. quadruple therapy for Helicobacter pylori infection -: a randomized trial [J].
Calvet, X ;
Ducons, J ;
Guardiola, J ;
Tito, L ;
Andreu, V ;
Bory, F ;
Guirao, R .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (07) :1261-1267
[7]  
Calvet X, 2000, ALIMENT PHARM THER, V14, P603
[8]  
CAMMAROTA G, 2000, ALIMENT PHARM THERAP, V14, P311
[9]  
Catalano F, 1998, ALIMENT PHARM THERAP, V12, P59
[10]   Two new treatment regimens for Helicobacter pylori eradication:: a randomised study [J].
De Francesco, V ;
Zullo, A ;
Hassan, C ;
Faleo, D ;
Ierardi, E ;
Panella, C ;
Morini, S .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (08) :676-679